Recent Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)

A number of research firms have changed their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX):

• 12/23/2024 – Neurocrine Biosciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock.
• 12/23/2024 – Neurocrine Biosciences had its price target raised by analysts at Barclays PLC from $160.00 to $165.00. They now have an “overweight” rating on the stock.
• 12/20/2024 – Neurocrine Biosciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 12/16/2024 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at William Blair.
• 12/16/2024 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
• 12/16/2024 – Neurocrine Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
• 11/11/2024 – Neurocrine Biosciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Neurocrine Biosciences Stock Down 0.4 %

Shares of NBIX traded down $0.56 during midday trading on Wednesday, hitting $136.50. The company’s stock had a trading volume of 689,088 shares, compared to its average volume of 881,323. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The stock has a market capitalization of $13.82 billion, a price-to-earnings ratio of 36.60 and a beta of 0.34. The company’s fifty day simple moving average is $126.79 and its two-hundred day simple moving average is $130.71.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. The trade was a 30.32 % decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Plato Investment Management Ltd boosted its position in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares during the last quarter. Swiss National Bank boosted its position in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences during the third quarter worth approximately $3,236,000. KBC Group NV increased its holdings in Neurocrine Biosciences by 78.3% in the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Neurocrine Biosciences by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock valued at $2,238,000 after buying an additional 7,597 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.